In a remarkable feat, ImmunoACT, supported by IIT-B and Laurus Labs, has won approval from the Central Drugs Standard Control Organization (CDSCO) for India’s very first CAR-T cell therapy called NexCAR19. This groundbreaking therapy is a major advancement in the treatment of relapsed/refractory (r/r) B-cell lymphomas and leukemia, signaling significant progress in advanced cell-and-gene therapies.
A Breakthrough from India
NexCAR19 is a special CAR-T cell therapy aimed at CD19, and it’s made entirely in India. This is a massive step forward for advanced cell-and-gene therapies.
Successful Clinical Trials
Researchers tested NexCAR19 on 60 patients with r/r B-cell lymphomas and leukemia, and the results are exciting. About 70 percent of the patients had a positive response to the therapy. What’s even more impressive is that NexCAR19 showed fewer side effects, setting it apart from other similar therapies. It means that it can be used to treat patients in places with fewer resources.
The Impact
The approval of NexCAR19 is a game-changer. Now, even in countries with limited resources, people can get this life-saving treatment at a reasonable cost. This achievement is like reaching for the stars, and it puts India among the few countries with access to CAR-T therapy. It’s a significant step forward in the battle against cancer.
